BEIJING, March 6 /PRNewswire-Asia/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that each of Mr. Xiaodong Wu, the Company’s Chairman and Chief Executive Officer, Mr. Sam Tsang, the Company’s Chief Financial Officer and Dr. Zhong Chen, the Company’s Chief Technology Officer, purchased the Company’s American Depositary Shares (“ADSs”) in the open market in the past two days.
Mr. Wu purchased 150,000 ADSs at an average price of US$13.07 per ADS. Mr. Tsang purchased 6,500 ADSs at an average price of US$13.15 per ADS. Dr. Chen purchased 5,000 ADSs at an average price of US$12.81 per ADS.
Mr. Wu has indicated to the Company that he may continue to purchase the Company’s ADSs in the open market in the future in compliance with the Company’s insider trading policy.
About China Medical Technologies, Inc.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .
For more information, please contact:
Winnie Yam
Tel: +86-10-6530-8833
Email: IR@chinameditech.com